Arthritis Rheumatoid Disease Severity in Patients with B, Is Associated
Total Page:16
File Type:pdf, Size:1020Kb
A Truncated Variant of ASCC1, a Novel Inhibitor of NF- κB, Is Associated with Disease Severity in Patients with Rheumatoid Arthritis This information is current as of September 25, 2021. Silvia Torices, Lorena Alvarez-Rodríguez, Lara Grande, Ignacio Varela, Pedro Muñoz, Dora Pascual, Alejandro Balsa, Marcos López-Hoyos, Víctor Martinez-Taboada and Jose L. Fernández-Luna J Immunol 2015; 195:5415-5420; Prepublished online 26 Downloaded from October 2015; doi: 10.4049/jimmunol.1501532 http://www.jimmunol.org/content/195/11/5415 http://www.jimmunol.org/ References This article cites 28 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/195/11/5415.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology A Truncated Variant of ASCC1, a Novel Inhibitor of NF-kB, Is Associated with Disease Severity in Patients with Rheumatoid Arthritis Silvia Torices,*,† Lorena Alvarez-Rodrı´guez,* Lara Grande,† Ignacio Varela,‡ Pedro Mun˜oz,x Dora Pascual,{ Alejandro Balsa,{ Marcos Lo´pez-Hoyos,‖ Vı´ctor Martinez-Taboada,*,# and Jose L. Ferna´ndez-Luna† Loss of the regulatory mechanisms that avoid excessive or constitutive activation of NF-kB may be associated with chronic inflammatory disorders, including rheumatoid arthritis (RA). After massive sequencing of 158 regulators of the NF-kB pathway in RA patients, we focused on a scarcely known gene, ASCC1, and showed that it potently inhibits the expression of NF-kB target genes (TRAIL, TNF-a, cIAP-1, IL8) and blocks activation of a NF-kB–luciferase reporter construct in five different human cell Downloaded from lines. Therefore, ASCC1 may contribute to avoiding a pathologic activation of this transcription factor. A truncated variant of ASCC1 (p.S78*) was found in RA patients and control individuals. Functional in vitro studies revealed that truncation abrogated the NF-kB inhibition capacity of ASCC1. In contrast with full-length protein, truncated ASCC1 did not reduce the transcriptional activation of NF-kB and the secretion of TNF-a in response to inflammatory stimuli. We analyzed the clinical impact of p.S78* variant in 433 patients with RA and found that heterozygous carriers of this variant needed more disease-modifying antirheu- matic drugs, and more patients with this genotype needed treatment with corticoids and biologic agents. Moreover, the truncated http://www.jimmunol.org/ allele-carrier group had lower rates of remission compared with the full-length variant carriers. Overall, our findings show for the first time, to our knowledge, that ASCC1 inhibits NF-kB activation and that a truncated and inactive variant of ASCC1 is associated with a more severe disease, which could have clinical value for assessing the progression and prognosis of RA. The Journal of Immunology, 2015, 195: 5415–5420. heumatoid arthritis (RA) is an autoimmune disease char- There is increasing evidence that NF-kB is a major, if not the acterized by progressive joint destruction caused by the main, transcription factor controlling inflammation (5). Activation of R chronic inflammation of the synovial tissue (1, 2). Al- the NF-kB pathway is involved in the pathogenesis of chronic in- by guest on September 25, 2021 though several genes have been suggested to be associated with flammatory disorders, including RA and inflammatory bowel disease RA, the genetic regulation that contributes to the development of (6, 7). NF-kB proteins are regulated by the inhibitor of NF-kBki- disease in these patients remains unclear (3, 4). nase (IkB) complex formed by inhibitor of NF-k kinase (IKK)a and IKKb and the regulatory subunit IKKg. This kinase complex phosphorylates IkB, which is subsequently ubiquitinated and de- *Servicio de Reumatologı´a, Hospital Universitario Marques de Valdecilla-Instituto de graded, thus leading to the activation of NF-kB (8, 9). In addition, Investigacio´n Valdecilla, 39011 Santander, Spain; †Unidad de Gene´tica, Hospital Uni- some members of the nucleotide-binding domain and leucine-rich versitario Marques de Valdecilla-Instituto de Investigacio´n Valdecilla, 39011 Santander, Spain; ‡Servicio de Reumatologı´a, Hospital Universitario La Paz, 08046 Madrid, repeat containing (NLR) family including NOD1, NOD2, NLR Spain; xSeccio´n de Inmunologı´a, Hospital Universitario Marques de Valdecilla- pyrindomaincontaining(NLRP)3,andNLRP2regulatetheactivity { Instituto de Investigacio´n Valdecilla, 39011 Santander, Spain; Instituto de Biomedicina of NF-kB (10, 11). Aberrant NF-kB signaling has been described y Biotecnologı´a de Cantabria (Universidad de Cantabria, Consejo Superior de Inves- tigaciones Cientı´ficas), 39011 Santander, Spain; ‖Gerencia Atencio´n Primaria, Servicio in various cancers and immune diseases. Gene variants of IKKb Ca´ntabro de Salud, 39011 Santander, Spain; and #Facultad de Medicina, Universidad de have been associated with colorectal cancer (12), lymphomas, mul- Cantabria, 39011 Santander, Spain tiple myeloma (13), and combined immunodeficiency (14). Previous ORCIDs: 0000-0002-0969-506X (I.V.); 0000-0002-1387-2655 (P.M.); 0000-0001- 8070-7062 (A.B.). work has also identified variants of MYD88 and TNFRSF11A that promote constitutive activation of NF-kB (15, 16). Our group has Received for publication July 8, 2015. Accepted for publication September 27, 2015. previously described that a truncating variant that abrogates the ca- This work was supported by the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation Grants PI11/02012 and RD12/0036/0022 from Red Tema´tica pacity of CARD8 to inhibit the NF-kB transcriptional activity is de Investigacio´n Cooperativa en Ca´ncer, Federacio´n Espan˜ola de Reumatologı´a associated with disease severity in RA patients (17). Grant FER13/13, Instituto de Investigacio´n Valdecilla Grant APG-03, and the pro- grama Ramo´n y Cajal, Ministerio de Economia y Competitividad, Spain (I.V.). ASCC1 encodes the p50 subunit of a protein complex, which includes ASCC2, ASCC3, and TRIP4 (also known as ASC1), Address correspondence and reprint requests to Dr. Jose L. Fernandez-Luna, Unidad de Gene´tica, Hospital Universitario Marques de Valdecilla-Instituto de Investigacio´n among others (18) involved in transcriptional regulation. TRIP4 Valdecilla, Avenida Cardenal Herrera Oria, 39011 Santander, Spain. E-mail address: contains a transactivation domain with a putative zinc finger motif, fl[email protected] which serves as a binding site for TATA-binding protein, TFIIA, Abbreviations used in this article: DMARD, disease-modifying antirheumatic drug; HUMV, Hospital Universitario Marques de Valdecilla; IkB, inhibitor of NF-kB ki- SRC1, CBP/p300, and nuclear receptors (19). It also interacts with nase; IKK, inhibitor of NF-k kinase; NGS, next-generation sequencing; NLR, nucleo- a wide range of transcription factors including serum response tide-binding domain and leucine-rich repeat containing; NLRP, NLR pyrin domain factor, NF-kB, and AP1, and has been shown to be part of a containing; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism. coactivator complex that links these factors to the transcriptional Copyright Ó 2015 by The American Association of Immunologists, Inc. 0022-1767/15/$25.00 machinery (18). Overexpressed TRIP4 has been normally local- www.jimmunol.org/cgi/doi/10.4049/jimmunol.1501532 5416 AN ASCC1 VARIANT ASSOCIATES WITH SEVERITY IN RA ized in the nucleus but accumulates in the cytoplasm under serum- ASCC1 was selected and analyzed in the other 367 patients with RA and deprived conditions (19). Thus, it is suggested that TRIP4 plays 184 age-matched control individuals. DNA was extracted from whole an important role in establishing distinct coactivator complexes blood by using the QIAamp DNA blood kit (Qiagen, Hamburg, Germany) and amplified with primers for human ASCC1: 59-TGAGGACTCATGG- under different cellular conditions (19). Very little is known about CAACAGC-39 and 59-ACTTGATAGCCCTGTGATGGC-39.Sequenceanal- the association between other members of the ASCC1-containing ysis of amplified fragments was carried out by Sanger sequencing. complex and disease. A recent study described a germline missense Expression analyses of NF-kB target genes mutation in exon 8 of ASCC1 (p.N290S) in patients with Barrett esophagus and esophageal adenocarcinoma (20), but no functional To assess the expression of individual genes, we generated and amplified a cDNA studies were shown. by using primers for human TNF-a (59-CAATGGCGTGGAGCTGAGAG-39 and 59-GGCTGATGGTGTGGGTGAGG-39), CCL2 (59-CTCGCTCAGCCA- A number of studies suggest that NF-kB is essential for the GATGCAAT-39 and 59-GTCTTCGGAGTTTGGGTTTGC-39), IL-8 (59-CTGG expression of both inflammatory cytokines and tissue-destructive